Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
CorVel Corporation provides technology-enabled managed care services for workers' compensation, auto insurance, and health insurance claims. The company operates proprietary software platforms (CareLink, CareMC) that automate medical bill review, utilization management, and network solutions for insurance carriers, third-party administrators, and self-insured employers across all 50 states. CorVel's competitive moat stems from its integrated technology stack and 40+ years of clinical expertise in medical cost containment.
CorVel generates revenue by reducing medical costs for payers through automated bill review (identifying billing errors, duplicate charges, upcoding), negotiating provider discounts via proprietary networks, and managing high-cost cases to prevent unnecessary treatments. Pricing power derives from demonstrable ROI—clients typically save $3-5 for every $1 spent on CorVel services. The company operates on a variable-cost model with technology amortization as the primary fixed cost, allowing 23.4% gross margins despite labor-intensive case management. High client retention (estimated 90%+ annually) and cross-selling opportunities drive recurring revenue.
Workers' compensation claim frequency and severity trends—declining workplace injury rates reduce addressable market but increase focus on cost containment per claim
New client contract wins and renewals with major insurance carriers (Liberty Mutual, Travelers, Zurich) and large self-insured employers
Technology platform adoption rates—percentage of claims processed through automated vs. manual workflows directly impacts margins
Regulatory changes to workers' compensation fee schedules and medical reimbursement rates across key states (California, Texas, Florida represent 40%+ of market)
Competitive pricing pressure from Sedgwick, Gallagher Bassett, and Mitchell International in bill review and network services
Long-term decline in workers' compensation claim frequency due to automation, remote work adoption, and improved workplace safety—frequency has dropped 3-4% annually over past decade, compressing market size
Healthcare price transparency regulations and reference-based pricing models could commoditize bill review services, reducing pricing power for proprietary networks
Vertical integration by major insurance carriers (Travelers, Liberty Mutual building in-house technology) threatens outsourcing model, particularly for largest accounts representing 20-30% of revenue
AI-driven medical bill review from tech entrants (Waystar, Change Healthcare) could disrupt labor-intensive case management with lower-cost automation
Sedgwick and Gallagher Bassett possess larger scale (3-5x revenue) enabling broader provider networks and lower per-unit costs in commoditized services
Mitchell International and Enlyte (formerly Mitchell + Genex) offer integrated auto and workers' comp solutions, creating switching costs CorVel cannot match as mono-line provider
Private equity consolidation in third-party administrator market increases buyer negotiating leverage, compressing CorVel's take rates on network savings
Minimal financial leverage (0.10 D/E) limits balance sheet risk, but $2.5B market cap and limited float create liquidity constraints for institutional investors
Working capital intensity (estimated 60-90 day cash conversion cycle) requires consistent cash generation to fund 12%+ revenue growth without external financing
Technology obsolescence risk—proprietary platforms require continuous $15-20M annual investment (estimated 2-3% of revenue) to maintain competitive functionality against cloud-native competitors
moderate - Workers' compensation claim volumes correlate with employment levels and industrial activity. Economic expansions increase workplace injuries (more workers, longer hours, construction activity), expanding CorVel's addressable market. However, recessions drive cost-cutting focus among insurers, potentially increasing demand for medical cost containment services. Healthcare cost inflation (running 5-7% annually) creates secular tailwind regardless of cycle as payers seek third-party expertise. The 12.6% revenue growth during recent period suggests resilient demand across cycles.
Rising interest rates have minimal direct impact on operations given negligible debt (0.10 D/E ratio) and limited financing needs. However, higher rates compress valuation multiples for high-quality compounders trading at 14.0x EV/EBITDA. Insurance carrier clients may face investment portfolio pressure in rising rate environments, potentially accelerating outsourcing of non-core functions like medical bill review to preserve capital. Current 1.85x current ratio and $0.1B operating cash flow provide ample liquidity without rate exposure.
Minimal direct credit exposure. CorVel's clients are primarily investment-grade insurance carriers and large corporations with strong payment histories. Receivables risk is low given 30-60 day payment terms typical in the industry. The company does not extend credit to medical providers or claimants. Balance sheet strength (17.7% ROA, 30.1% ROE) reflects asset-light model with limited credit-dependent growth.
value - The 58.4% one-year decline despite 12.6% revenue growth and 24.8% earnings growth suggests quality compounder trading at distressed valuation. 30.1% ROE, minimal debt, and 3.6% FCF yield attract value investors seeking mispriced cash generators. However, limited float and $2.5B market cap restrict institutional ownership. Recent 32.3% three-month decline may reflect tax-loss harvesting or forced selling rather than fundamental deterioration. Typical shareholder profile includes long-only value funds and quantitative strategies screening for quality factors (high ROE, low debt, positive FCF).
moderate-to-high - The 58.4% annual drawdown significantly exceeds typical financial services volatility, suggesting elevated beta (estimated 1.3-1.5x) or company-specific issues. Small-cap status ($2.5B market cap) and limited analyst coverage amplify price swings on modest volume. Operating performance stability (consistent margin expansion, positive FCF) contrasts with stock price volatility, indicating sentiment-driven rather than fundamental volatility. Investors should expect 20-30% annual volatility given illiquidity and growth stock de-rating environment.
